PridCor Therapeutics Advances Long COVID Treatment with Peer-Reviewed Publication and FDA IND Exemption for Phase 2 SHIELD Study
核心洞察
PridCor Therapeutics (搜索) published peer-reviewed clinical case series data in Frontiers in Immunology showing substantial improvements in Long COVID (搜索) symptoms including fatigue (搜索), dysautonomia (搜索), and cognitive impairment (搜索) with their combination antiviral regimen.
The FDA granted an IND exemption for PridCor's upcoming SHIELD Study, allowing the Phase 2 randomized, double-blind, placebo-controlled trial to proceed without typical regulatory delays.
The SHIELD Study will launch in Q1 2026 in collaboration with Mount Sinai's Icahn School of Medicine, led by recognized Long COVID (搜索) experts David Putrino, PhD, and Amy Proal, PhD.
PridCor Therapeutics (搜索) announced two significant milestones advancing its Long COVID (搜索) treatment program, including peer-reviewed publication of clinical case series data and FDA regulatory clearance for its upcoming Phase 2 clinical trial. The clinical-stage biopharmaceutical company develops antiviral therapies for infection-associated chronic illnesses, positioning itself to address a major unmet medical need affecting millions worldwide.
Peer-Reviewed Data Demonstrates Clinical Promise
The company's clinical case series, published in Frontiers in Immunology under the title "Patient-reported improvements from use of IMC-2 alone and IMC-2 and Paxlovid® in a Long COVID (搜索) cohort: a case series," reports substantial improvements across several debilitating Long COVID symptoms. Patients treated with PridCor's combination antiviral regimen showed improvements in fatigue (搜索), dysautonomia (搜索), and cognitive impairment (搜索) commonly described as brain fog.
The study provides uncommon long-term observational data, with patient follow-up extending as long as 731 days. This extended monitoring period offers valuable insights into a disease state where symptoms frequently persist for years and effective treatment options remain lacking. Patients receiving the combination antiviral regimen experienced greater and more sustained symptom improvement compared to those receiving alternative therapy.
FDA Grants IND Exemption for Accelerated Development
In parallel with the publication, PridCor received confirmation from the FDA that its planned Long COVID (搜索) clinical study qualifies for an Investigational New Drug (IND) exemption. This regulatory determination allows the SHIELD Study to proceed without the typical delays associated with the IND application process.
The IND exemption enables PridCor to use FDA-approved medications meeting established clinical criteria while maintaining rigorous oversight through institutional review board supervision, informed consent requirements, and applicable Good Clinical Practice standards.
"These milestones strengthen both the scientific and regulatory underpinnings of our SHIELD Study," said Dr. William Pridgen, Co-Founder and Chief Executive Officer of PridCor Therapeutics (搜索). "Peer-reviewed publication confirms that our early clinical observations merit further investigation, and the IND exemption allows us to advance efficiently while maintaining rigorous ethical and regulatory standards."
SHIELD Study Design and Leadership
PridCor plans to initiate the SHIELD Study in Q1 2026, a randomized, double-blind, placebo-controlled Phase 2 clinical trial conducted in collaboration with the Icahn School of Medicine at Mount Sinai. The study aims to rigorously evaluate the safety and potential efficacy of PridCor's antiviral regimen in patients with Long COVID (搜索).
The trial will be led by David Putrino, PhD, Director of Rehabilitation Innovation and Nash Family Director at the Cohen Center for Recovery from Complex Chronic Illnesses at Mount Sinai. Dr. Putrino brings extensive experience in Long COVID (搜索) and infection-associated chronic conditions. Amy Proal, PhD, President and CEO of PolyBio Research Foundation (搜索), will serve as Co-Investigator.
Addressing Significant Medical Need
Long COVID (搜索) affects millions of individuals worldwide, resulting in significant societal and economic costs. Patients often experience persistent fatigue (搜索), neurological symptoms, autonomic dysfunction, and reduced quality of life long after acute infection. The condition represents a major unmet medical need due to lack of viable treatments, prolonged workforce disruptions, and long-term disability in affected patients.
PridCor's development strategy targets the theory that persistent viral activity and immune dysregulation contribute to ongoing symptoms in a subset of patients, necessitating a combination antiviral regimen. The company's lead investigational approach, the Combo Regimen (搜索), combines multiple antiviral agents with complementary mechanisms of action to target persistent viral activity and improve patient outcomes.